Pilocarpine ( DrugBank: Pilocarpine )

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
53	Sjogren syndrome	5
299	Cystic fibrosis	3

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041180018	04/09/2017	20/12/2018	Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease	Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease	Parkinson's disease and related diseases	Two drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eye	katsuno Masahisa	NULL	Complete	>= 40age old	Not applicable	Both	40	Phase 2	Japan
2	JPRN-UMIN000026128	2017/04/01	01/04/2017	Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease		Parkinson's disease	administe pilocarpine and dipivefrine administe pilocarpine and dipivefrine	Nagoya University	NULL	Recruiting	40years-old	90years-old	Male and Female	60	Not selected	Japan

53. Sjogren syndrome

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000010796	2013/06/01	24/05/2013	Impact of CYP2A6 and CHRM3 genetic polymorphisms on the PK/PD of pilocarpine in Japanese healthy volunteers		Sjogren's syndrome	single oral administration of pilocarpine. salagen (KISSEI PHARMACEUTICAL CO.,LTD.) 5mg 1Tablet.	Oita University Faculty of Medicine	NULL	Pending	20years-old	Not applicable	Male and Female	30	Not applicable	Japan
2	JPRN-UMIN000029307	2009/02/01	27/09/2017	Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients		Sjogren's syndrome	Pilocarpine / sodium alginate solution (0.32 mL, pilocarpine 0.96 mg) is administered intra-orally 3 times a day for 7 days.	Teikyo University	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	50	Not selected	Japan
3	JPRN-UMIN000001460	2008/10/01	29/10/2008	The efficacy and safety of pirocarpine hydrochloride for juvenile Sjogren's syndrome		Sjogren's syndrome	Oral pilocarpine hydrochloride for 4 weeks.	Department of Pediatrics, Graduate School of Medicine, Chiba Univerity	NULL	Complete: follow-up complete	6years-old	16years-old	Male and Female	10	Not selected	Japan
4	NCT00438048 (ClinicalTrials.gov)	November 2006	20/2/2007	A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment	Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva	Primary Sjogren;Secondary Sjogren;Xerostomia	Procedure: pilocarpine;Drug: Artificial Saliva	Pontificia Universidad Catolica de Chile	Formulario MAgistral Farmacias Ahumada	Completed	18 Years	N/A	Both	76	Phase 4	Chile
5	NCT04470479 (ClinicalTrials.gov)	March 1, 2005	7/7/2020	Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome	Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome	Dry Eye	Drug: Pilocarpine Hydrochloride;Drug: Placebo	Federal University of São Paulo	NULL	Completed	18 Years	65 Years	All	32	Phase 3	Brazil

299. Cystic fibrosis

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04732195 (ClinicalTrials.gov)	January 20, 2022	25/1/2021	Pilocarpine Microneedles for Sweat Induction (PMN-SI)	A Pilot Study to Compare the Efficacy of Pilocarpine Microneedles With Iontophoresis Method for Sweat Induction in Healthy Human Subjects	Cystic Fibrosis	Device: Pilocarpine microneedle patch;Device: Pilocarpine Iontophoresis	Emory University	Georgia Institute of Technology	Recruiting	18 Years	N/A	All	50	N/A	United States
2	NCT03584841 (ClinicalTrials.gov)	March 31, 2017	27/5/2018	Implementation of a Non-invasive Version of the Imaging ß-adrenergic-dependent Sweat Secretion Test	Implementation of a Non-invasive Version of the Imaging ß-adrenergic-dependent Sweat Secretion Test: Value for Diagnosis and Efficacy of Target Therapies for Cystic Fibrosis	Mucoviscidosis Involving the Lung	Diagnostic Test: Iontophoresis sessions in forearm of subjects with pilocarpine	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	NULL	Recruiting	18 Years	100 Years	All	120	N/A	Belgium
3	NCT02310789 (ClinicalTrials.gov)	July 31, 2015	3/9/2014	(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?	(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory Coil	Cystic Fibrosis	Drug: Ivacaftor;Drug: ß-Adrenergic cocktail;Drug: Pilocarpine Nitrate 5%;Device: Macroduct sweat stimulator	Richard Barry Moss	NULL	Completed	18 Years	N/A	All	8	N/A	United States